MDxHealth is trading at $0.18, down 5.10%, with no specific catalyst identified for the October 29 decline.
- The latest company-specific news located was the October 15 preliminary Q3 revenue announcement and suspension of full-year guidance.
- Analyst downgrades followed that guidance news, but neither it nor the downgrades establishes a cause for this session’s move.